TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24387695
Drug: MK-2206 200
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 200 mg Q3W with docetaxel 75 mg/m2
Study: 24387695
Drug: MK-2206 135
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 135 mg QW with erlotinib 100 or 150 mg daily
Study: 24387695
Drug: MK-2206 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 (various doses)
Study: 24388332
Drug: Autologous umbilical
Normalized name: Autologous umbilical cord blood
DrugBank: Autologous cord blood (DB17926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous umbilical cord blood (UCB) cells, up to 4 doses adjusted for volume and red blood cell content, 1-5 × 10(7) cells/dose
Study: 24388695
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg levonorgestrel (LNG) taken shortly after sex
Study: 24389297
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg administered subcutaneously at baseline, week 4, and week 16
Study: 24393475
Drug: Higher fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher fasting glucose levels (6.39±0.49 vs 6.24±0.43 mmol/L)
Study: 24395025
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of TIV and PCV13
Study: 24398331
Drug: Corticosteroid-sparing treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid-sparing treatments
Study: 24399330
Drug: Active hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active hormone therapy
Study: 24399330
Drug: Placebo hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo hormone therapy
Study: 24400847
Drug: Beta-blocker treatment
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker treatment (mean daily doses: bisoprolol 5.5 mg, metoprolol 73.7 mg)
Study: 24400912
Drug: Set-valued dynamic
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Set-valued dynamic treatment regimes (DTRs) that accommodate competing outcomes.
Study: 24402746
Drug: Recalcitrant disease
Normalized name: LYME DISEASE VACCINE
DrugBank: Lyme disease vaccine (recombinant OspA) (DB00045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recalcitrant disease and aspirin intolerance
Study: 24402982
Drug: Accelerated Resolution
Normalized name: Revolution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Resolution Therapy (ART) - 2 sessions
Study: 24407191
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg b.d. and irinotecan 180 mg m(-2) every 2 weeks (Phase II)
Study: 24410126
Drug: Gd-DTPA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gd-DTPA (1 mM) and IL13-PE (0.125 μg/ml)
Study: 24410126
Drug: Gd-DTPA (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gd-DTPA (5 mM) and IL13-PE (0.25 μg/ml)
Study: 24410943
Drug: Amiloride 10
Normalized name: amiloride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 10 mg daily for 4 weeks
Study: 24411228
Drug: Two-week schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-week schedule of radiotherapy with oral capecitabine (1650 mg/m²/day)
Study: 24412141
Drug: Adrenocorticotropic hormone-independent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenocorticotropic hormone-independent CS (AICS)
Study: 24412228
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg twice daily until disease progression
Study: 24414130
Drug: Local determination
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local determination of HER2 receptor status
Study: 24414130
Drug: Central determination
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central determination of HER2 receptor status
Study: 24414130
Drug: Local determination
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local determination of ER receptor status
Study: 24414130
Drug: Central determination
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central determination of ER receptor status
Study: 24414130
Drug: Local determination
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local determination of PR receptor status
Study: 24414130
Drug: Central determination
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central determination of PR receptor status
Study: 24414130
Drug: Treatment plan
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment plan alteration based on receptor status change
Study: 24415536
Drug: Chemotherapy (protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (protocol I, 3 polychemotherapy blocks, delayed intensification, cranial radiotherapy, and maintenance for 2 years)
Study: 24415536
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for patients with only prednisone poor response (PPR)
Study: 24415536
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for MRD-HR patients
Study: 24415536
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for patients with no CR at day 33
Study: 24415536
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for patients with t(4;11) translocation
Study: 24415560
Drug: Oral clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral clofarabine (1 mg to 6 mg daily for 14 or 21 days of a 28-day cycle, for up to five cycles)
Study: 24416138
Drug: Sorafenib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (200 mg/day)
Study: 24416138
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg/day)
Study: 24416138
Drug: Sorafenib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (800 mg/day)
Study: 24416138
Drug: Gemcitabine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (300 mg/m2 i.v. weekly ×5 weeks) with radiation therapy (45 Gy in 25 fractions)
Study: 24418731
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy for pump thrombus
Study: 24420643
Drug: Teriparatide (PTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (PTH 1-34) 20 mcg sc daily for 24 months
Study: 24422672
Drug: Combination targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination targeted therapy consisting of sorafenib, temsirolimus, and bevacizumab
Study: 24423045
Drug: 2:1 formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2:1 formulation of follitropin alfa and lutropin alfa
Study: 24423285
Drug: LCI699 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCI699 (4 mg/d, escalated to 10, 20, 40, and 100 mg/d as needed)
Study: 24423301
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel 120 mg administered sc every 28 days
Study: 24423476
Drug: Dexamethasone infusion
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone infusion (4 mg/mL) via adventitial microinfusion catheter
Study: 24427455
Drug: Neostigmine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 50 µg/kg with glycopyrrolate 10 µg/kg
Study: 24428625
Drug: PEG-asparaginase (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-asparaginase (1000 iu/m2/dose, intramuscular, 8 or 15 doses at 2-6 weeks intervals, total exposure 30 weeks)
Study: 24428927
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hemoglobin ≤ 10 g/dL and RDW >15%
Study: 24429069
Drug: Live oral
Normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live oral Salmonella enterica serovar Typhi vaccine Ty21a
Study: 24429069
Drug: Live oral
Normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live oral S. Typhi vaccine CVD 909
Study: 24429311
Drug: Day 7
Normalized name: Pataday 7 MG/ML Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 7 total RMP level (cut-off 12.50 mg/l)
Study: 24429336
Drug: Lenalidomide 15
Normalized name: lenalidomide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 15 mg/day (days 1-14), bortezomib 1.0 mg/m² (days 1, 4, 8, and 11), dexamethasone 40/20 mg/day (cycles 1-4) and 20/10 mg/day (cycles 5-8)
Study: 24429497
Drug: Carfilzomib (escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (escalated from 20 to 45 mg/m² on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle)
Study: 24429497
Drug: Carfilzomib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib (45 mg/m²), ascorbic acid (1000 mg), and cyclophosphamide (2.2 mg/kg)
Study: 24431228
Drug: Ofatumumab (OFA)
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab (OFA) therapy
Study: 24431907
Drug: Empirical antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical antifungal therapy with itraconazole
Study: 24431909
Drug: Continuous erythropoietin
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous erythropoietin receptor activator (CERA) administered intravenously once every 2 weeks (n=39)
Study: 24431909
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta administered thrice-weekly (n=41)
Study: 24432743
Drug: Blueberry juice
Normalized name: lowbush blueberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry juice (250 mL)
Study: 24433194
Drug: Azithromycin mass
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin mass drug administration (three annual treatments)
Study: 24433194
Drug: Baseline-only treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline-only treatment
Study: 24433481
Drug: Basal UCP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal UCP I/(I + III) ratio before MTX infusion (P1)
Study: 24433481
Drug: UCP I/(I
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCP I/(I + III) ratio at the end of MTX infusion (P2)
Study: 24434094
Drug: Customized adherence
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized adherence enhancement plus long-acting injectable antipsychotic (haloperidol decanoate) for 6 months
Study: 24434370
Drug: mtDRV/rtv (800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: mtDRV/rtv (800/100 mg every 24 h)
Study: 24435467
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil (EPO) 4-6 g daily for 12 weeks
Study: 24438153
Drug: Calcium phosphate
Normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium phosphate (CaP) - additional 1 g calcium/d
Study: 24438153
Drug: Vitamin D₃
Normalized name: vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D₃ - additional 10 μg/d
Study: 24438203
Drug: Self-administered icatibant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered icatibant (30-mg subcutaneous injection)
Study: 24438203
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of icatibant
Study: 24438203
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (HCP administered icatibant prior to self-administration)
Study: 24439297
Drug: AAV.REP1 (0·6-1·0×10(10)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV.REP1 (0·6-1·0×10(10) genome particles, subfoveal injection)
Study: 24439297
Drug: Control eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control eyes (not specified treatment)
Study: 24439931
Drug: Cixutumumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab (20 mg/kg) administered intravenously every 3 weeks until disease progression or intolerable toxic effects
Study: 24440085
Drug: LY2584702 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2584702 75 mg BID
Study: 24440085
Drug: LY2584702 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2584702 100 mg QD
Study: 24440085
Drug: LY2584702 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2584702 (various doses)
Study: 24440112
Drug: 1-dose PCV7
Normalized name: pneumococcal 7-valent conjugate vaccine (PCV7) 0.5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-dose PCV7
Study: 24440112
Drug: 2-dose PCV7
Normalized name: pneumococcal 7-valent conjugate vaccine (PCV7) 0.5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose PCV7
Study: 24440279
Drug: Sorafenib 400mg
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400mg twice daily continuously until disease progression or intolerable toxicity
Study: 24442098
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) 6.25 mg/kg orally twice daily
Study: 24444339
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of 2 G-eNOS allele (rs1799983) in both men and women
Study: 24444526
Drug: Oral epigallocatechin-3-gallate
Normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral epigallocatechin-3-gallate (EGCG) administered three times a day after the occurrence of grade 2 esophagitis, with dose escalation at six concentration levels.
Study: 24444526
Drug: Oral epigallocatechin-3-gallate
Normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral epigallocatechin-3-gallate (EGCG) administered three times a day after the occurrence of grade 2 esophagitis.
Study: 24445353
Drug: Okada purifying
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Okada purifying therapy (OPT), administered every weekday for 1 year by certified practitioners.
Study: 24445353
Drug: Okada purifying
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Okada purifying therapy (OPT).
Study: 24445595
Drug: High-dose hemithoracic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hemithoracic intensity-modulated radiation therapy (IMRT) followed by extrapleural pneumonectomy (EPP)
Study: 24447083
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of inhaled glucocorticosteroids (1700 μg)
Study: 24447083
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of oral glucocorticosteroids (6.7 mg)
Study: 24449167
Drug: Maltodextrins with
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrins with glutamine (0.117 g kg(-1) h(-1))
Study: 24449167
Drug: Maltodextrins alone
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrins alone (0.25 g kg(-1) h(-1), control)
Study: 24449716
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive strategy post-fibrinolysis with GPIIb/IIIa inhibitors
Study: 24449716
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive strategy post-fibrinolysis without GPIIb/IIIa inhibitors
Study: 24449716
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy post-fibrinolysis with GPIIb/IIIa inhibitors
Study: 24449716
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy post-fibrinolysis without GPIIb/IIIa inhibitors
Study: 24450444
Drug: Early response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early response to treatment (TCS ≤4 days)
Study: 24450444
Drug: Later response
Approvals — FDA: no, EMA: no, PMDA: no
Description: Later response to treatment (TCS >4 days)
Study: 24452648
Drug: Non-opioid analgesics
Normalized name: Non-opioid analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid analgesics (NSAIDs) in Pain Group (PG)
Study: 24452648
Drug: Non-opioid analgesics
Normalized name: Non-opioid analgesics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid analgesics (NSAIDs) in Surgical Group (SG)
Study: 24452648
Drug: Other drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs in Pain Group (PG)
Study: 24452648
Drug: Other drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs in Surgical Group (SG)
Study: 24452648
Drug: Psychotropic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic drugs in Pain Group (PG)
Study: 24452648
Drug: Psychotropic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic drugs in Surgical Group (SG)
Study: 24452746
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg once daily for 14 days followed by a single dose of colchicine 0.6 mg co-administered with atorvastatin 40 mg
Study: 24452746
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of colchicine 0.6 mg
Study: 24455219
Drug: Second 200,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second 200,000 IU capsule of vitamin A
Study: 24455283
Drug: Municipal hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Municipal hospital treatment
Study: 24455735
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray (2 puffs on cervical mucosa)
Study: 24455735
Drug: Oral dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexketoprofen trometamol (25 mg)
Study: 24456220
Drug: Maternal antenatal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal antenatal melatonin administration via intravenous infusion until term
Study: 24456586
Drug: Romidepsin 14
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin 14 mg/m2 as a 4-hour intravenous infusion on days 1, 8, and 15 every 28 days for up to 6 cycles; patients with response or stable disease could continue beyond 6 cycles.
Study: 24456794
Drug: LY2584702 (50-200mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2584702 (50-200mg) + erlotinib (150mg once daily)
Study: 24456794
Drug: LY2584702 (50-200mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY2584702 (50-200mg) + everolimus (10mg once daily)
Study: 24457244
Drug: GSK525762 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK525762 (a novel, orally bioavailable bromodomain and extra terminal inhibitor)
Study: 24457379
Drug: Pertuzumab (840-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab (840-mg loading dose and 420-mg maintenance intravenously every 3 weeks) and erlotinib (150-mg or 100-mg dose orally, daily)
Study: 24459219
Drug: Thiotepa and
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thiotepa and reduced-dose CYC
Study: 24460975
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (15 ml) deposited above the femoral nerve (Group A)
Study: 24460975
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (15 ml) deposited below the femoral nerve (Group B)
Study: 24460975
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (15 ml) deposited circumferential to the femoral nerve (Group C)
Study: 24463454
Drug: Empagliflozin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (25 mg) single dose
Study: 24463454
Drug: Empagliflozin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (25 mg) chronic treatment
Study: 24464121
Drug: Stabilized hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stabilized hyaluronic acid gel (HA)
Study: 24464355
Drug: Pazopanib 400
Normalized name: PAZOPanib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 400 mg/day on day 1 followed by 800 mg/day from day 2 onward
Study: 24464355
Drug: Pazopanib 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 1,000 mg/day
Study: 24464355
Drug: Pazopanib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib plus lapatinib (400/1,000 mg, 800/1,000 mg, 400/1,500 mg, 600/1,250 mg)
Study: 24464355
Drug: Pazopanib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib monotherapy (800 mg and 1,000 mg) and pazopanib plus lapatinib (any doses)
Study: 24465046
Drug: 2.5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 µg sufentanil plus 0.5% levobupivacaine (2.2 ± 0.2 mL)
Study: 24465046
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg fentanyl plus 0.5% levobupivacaine (2.2 ± 0.2 mL)
Study: 24465046
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine (2.2 ± 0.2 mL)
Study: 24467979
Drug: Interleukin-10 treatment
Normalized name: interleukin-10
DrugBank: Interleukin-10 (DB12880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-10 treatment